The lack of correlation between clinical signs and symptoms of dry eye disease makes diagnosing and treating patients a challenge. Often times, inflammation is present before the clinical signs of dry eye. InflammaDry is the first and only, rapid result, in-office test that detects elevated levels of MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry eye disease. All other dry eye tests measure tear production and stability. Using a simple 4-step process, InflammaDry recognizes elevated levels of MMP-9, to identify patients that may otherwise be missed with other dry eye testing methods.

Using direct sampling microfiltration technology, InflammaDry accurately identifies elevated levels of MMP-9 protein in tear fluid samples taken from the inside lining of the lower eyelid, the palpebral conjunctiva.

InflammaDry provides highly accurate results: 85% sensitivity, 94% specificity¹

InflammaDry is a disposable, low cost test, that requires no additional equipment to administer or interpret results. Using four simple steps, InflammaDry test results are achieved in just 10 minutes, aiding in the diagnosis of dry eye before the patient leaves the office.

By implementing InflammaDry into your practice, you can:

• Make a rapid, accurate diagnosis at the point-of-care
• Reduce complications associated with dry eye
• Help improve clinical outcomes and patient quality of life
• Identify and treat dry eye disease prior to surgery for better post-operative outcomes

Visit QuidelEyeHealth.com for additional information and training material.

References

¹ RPS InflammaDry sensitivity and specificity was compared to clinical truth in RPS clinical study: protocol #100310.